Nuvation Bio (Nuvation Bio) Accounts Receivable : $0.00 Mil (As of Sep. 2021)

View and export this data going back to 2020. Start your Free Trial

What is Nuvation Bio Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Nuvation Bio's accounts receivables for the quarter that ended in Sep. 2021 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Nuvation Bio's Net-Net Working Capital per share for the quarter that ended in Sep. 2021 was $3.51.

Nuvation Bio Accounts Receivable Historical Data

The historical data trend for Nuvation Bio's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Accounts Receivable Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Accounts Receivable

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Accounts Receivable	Get a 7-Day Free Trial			-	-	-	-	-

Nuvation Bio Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Nuvation Bio Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Nuvation Bio's Days Sales Outstanding for the quarter that ended in Sep. 2021 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Nuvation Bio's accounts receivable are only considered to be worth 75% of book value:

Nuvation Bio's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2021 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(791.784	+	0.75 * 0	+	0.5 * 0	-	28.425
-	0	-	0)	/	217.776
=	3.51

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Nuvation Bio Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company. The company is engaged in developing therapeutic candidates for the unmet needs in oncology. The firm operates in pharmaceutical, biotechnology and other related markets that develop small molecules and drug conjugates as treatments for cancer patients.